Slide 1: Corporate presentation
Corporate presentation September 2016 For personal use only Cover sheet to be added – Simone AGM Presentation – October 2023 David Burton – Chairman, CEO dburton@compumedics.com.au David Lawson – Director, CFO dlawson@compumedics.com.au Sleep Diagnostics & Treatment - Neuro Diagnostics - Brain Resea
Slide 2: Purpose of the meeting
Purpose of the meeting For personal use only • Compumedics overview and key growth inflection points • Current breakout commercial traction and corresponding share value drivers • Identify and execute strategies that will realise shareholder value and liquidity across our three core businesses.
Slide 3: Who is Compumedics?
Who is Compumedics? For personal use only Compumedics is a leading global medical technology company focused on: • Monitoring and diagnosing sleep disorders, including our new Somfit SaaS technology platform • Monitoring neurological disorders and highly sophisticated brain analysis, including our n
Slide 4: Revenue Composition – H1 FY25 - $23.5m
Revenue Composition – H1 FY25 - $23.5m SaaS/Annuity revenues grow from 23% of H1 FY23 revenues to 29% of H1 FY25 revenues For personal use only By geographic region By business / product group - global H1 FY25 Europe, AUD H1 FY23 H1 FY24 H1 FY25 v FY24 18% Sleep - capital 5.0 6.1 8.7 44% Sleep - Saa
Slide 5: H1 FY25 – key achievements
H1 FY25 – key achievements For personal use only • Significant growth returns to the key USA market, with sales order growth of 208% H1 FY25 compared to H1 FY24 for the total USA business. The growth was primarily driven by the sleep business • First revenues for Somfit in the USA HST market - $1m i
Slide 6: H2 FY25 – key milestones to watch for
H2 FY25 – key milestones to watch for For personal use only FY25 Guidance – revenues of more than $55m and EBITDA about $5m • Continued strong growth from our USA business across all products • Continued Somfit SaaS revenue growth in the USA in the fast- growing HST market segment • Somfit expansion
Slide 7: FY25 – from H1 FY25 to FY25 – sales orders taken
FY25 – from H1 FY25 to FY25 – sales orders taken For personal use only Strong H1 sales orders taken to underpin H2 revenues, with further growth in key global markets including a further uplift in Sleep Somfit SaaS H1 FY25 v AUD H1 FY23 H1 FY24 H1 FY25 FY24 Sleep - capital 3.5 4.8 16.6 248% Sleep -
Slide 8: FY25 – from H1 FY25 to FY25
FY25 – from H1 FY25 to FY25 For personal use only H2 FY25 v • Revenues to drive H2 FY25 AUDm H1 FY25 FY 25 H2 FY25 H2 FY24 H2 FY24 earnings turnaround – H1 FY25 Revenues 23.5 55.4 31.9 23.3 8.6 sales orders taken 75% higher Gross Margin 12.8 31.0 18.2 11.6 6.6 than H1 FY24 Gross Margin % 54.5% 56.0%
Slide 9: Business unit - Sleep
Business unit - Sleep For personal use only Sleep Diagnostics and Monitoring • Regarded as a world leader in sleep technology • Based on 35+ years of research and product development in sleep diagnostics/monitoring • $23.5m of revenues in FY24, including $4.2m of SaaS revenues with release of Somfit
Slide 10: Somfit – a new SaaS business moving from the sleep clinic eventually to the consumer
Somfit – a new SaaS business moving from the sleep clinic eventually to the consumer For personal use only Somfit builds on technical and clinical pedigree of Compumedics developed over the past 30+ years Somfit Consumer use Expand platform technology, in a consumer environment providing actionable
Slide 11: Somfit - Superior value proposition
Somfit - Superior value proposition For personal use only Somfit provides a more comfortable, convenient, and cost-effective way to assess and monitor sleep health. • Highly scalable: quality health SaaS business model. • Clinical grade at home device: Light and comfortable for the patient while ena
Slide 12: Sleep Diagnostics and Monitoring – addressable market
Business unit - Sleep For personal use only Sleep Diagnostics and Monitoring – Total and Compumedics (CMP) direct addressable market In the USA about 80% of people with a sleep disorder go undiagnosed – 60m people • Existing sleep lab-based business (capital equipment) – market size in the USA is ab
Slide 13: Sleep Diagnostics and Monitoring – revenue scenarios
Business unit - Sleep For personal use only Sleep Diagnostics and Monitoring – revenue scenarios Potential revenue scenarios - • Products used by sleep professionals & service providers to USDm identify people with sleep disorders 80 • Simpler screening products, like Somfit, address global bottlene
Slide 14: Business unit - Neuro
Business unit - Neuro For personal use only Neuro Diagnostics and brain research analytics • Expanded into neuro diagnostics in early 2000’s with the acquisition of USA-based Neuroscan, a leading brain analytics business • Regarded as an innovative technology provider to neurologists globally • $21.
Slide 15: Neuro Diagnostics and Monitoring – Direct and existing addressable market
Business unit - Neuro For personal use only Neuro Diagnostics and Monitoring – Direct and existing addressable market AUDm Clinical and neuro research annual MEG annual revenues (capital in nature) – revenues – (capital in nature) – currently around 5 to 10 systems pa but growing at up to 7% pa pote
Slide 16: MEG – The market
MEG – The market For personal use only How big is the market? • There are close to 200 active MEG labs globally. That number is growing every year. About ten new systems are sold each year. Three investment scenarios 1 Ongoing current traction 2 Major inflection where MEG scales up for brain functio
Slide 17: Neuro Diagnostics – revenue scenarios
Business unit – Neuro For personal use only Neuro Diagnostics – revenue scenarios Potential sales orders taken • Products used by neurologists to diagnose and scenarios MEG - USDm monitor people with a range of neurological disorders, including epilepsy 30 • Innovative neurological products, like Ok
Slide 18: Business unit - DWL
Business unit - DWL For personal use only Ultrasonic blood flow monitoring [Trans Cranial Doppler (TCD)] • Expanded into TCD (ultra sonic monitoring of blood pressure through the brain) with the acquisition of Germany-based DWL in 2004 • $4.3m of revenues in FY24, usually about $6.0m pa, impacted by
Slide 19: Business unit – DWL step-out growth option
Business unit – DWL step-out growth option For personal use only • DWL’s® new AI Robotic TCD development, opens the pathway to investigate strategic collaboration or other major deal opportunities, to assist accelerated commercialisation of this new technology. • The Robotics and AI health markets a
Slide 20: H2 FY25 – key milestones to watch for
H2 FY25 – key milestones to watch for For personal use only FY25 Guidance – revenues of more than $55m and EBITDA about $5m • Continued strong growth from our USA business across all products • Continued Somfit SaaS revenue growth in the USA in the fast- growing HST market segment • Somfit expansion
Slide 21: Value opportunity – FY2025
Value opportunity – FY2025 For personal use only Key growth Inflection points and commercial traction are becoming evident for: • Somfit – new 5 year pharmacy based supply agreement with Philips in Australia ($3m) underpins growth in Somfit/Nexus 360 SaaS revenues which were $4.2m for FY24, and $2.9
Slide 22: compumedics.com.au
For personal use only compumedics.com.au 23
Slide 23: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Compumedics Limited (CMP). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliabili